Journals (beta)
Posted by kinasepro on January 28, 2007
Mitsubishi has an app covering the intermediates for their GSK3 Sanofi-Aventis stuff. I still think the spiro compounds are sexier, but the morpholines are further explored so here we have a pretty solid looking asymmetric method to make 2-aryl morpholines via CBS reduction:
CCl)C=C1](http://img370.imageshack.us/img370/7310/untitled2kq6.jpg)
CNCC2=CC=CC=C2)C=C1 FC1=CC=C([C@H](OC2)CN(CC3=CC=CC=C3)C2=O)C=C1](http://img252.imageshack.us/img252/4789/mypicture5ii5.gif)
![FC1=CC=C([C@H]2CN(CC3=CC=CC=C3)CCO2)C=C1 FC1=CC=C([C@H]2CNCCO2)C=C1](http://img167.imageshack.us/img167/8666/mypicture6vl3.gif)
Route starts on page 79 example 1, 2 & 5 shown here.
Array might have something to say with how novel the approach is, y’know given how they sell the (rac) stuff?
Posted in GSK3, Mitsubishi, Sanofi-Aventis | 2 Comments »
Posted by kinasepro on January 14, 2007
US20070010539 is a GSK3-beta application. This series goes back to ’01, and the pictured spiro compound hit the streets in ’05. Publications on these? Other then an expert opinion (which my library doesn’t carry) and them naming SAR502250 a preclinical development candidate (also in ‘05), I haven’t seen anything. While I don’t relish posting old news, the novel spiro architecture was enough to make KP lift an eyebrow.
C4=CC=CC=C4)C5(CCN(C)CC5)CCN31](http://img296.imageshack.us/img296/6892/sa1ii9.jpg)
Only they know if these spiro compounds are the lead structures, but it looks like a well developed chemical series with an interesting story to be told, and since they’re not talking… I will.
Posted in GSK3, Mitsubishi, Sanofi-Aventis | Leave a Comment »
